Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Trial Profile

A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2019

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Acronyms ASCEND-1
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 13 May 2019 Status changed from active, no longer recruiting to completed.
    • 23 Apr 2019 Status changed from recruiting to active, no longer recruiting.
    • 27 Mar 2019 Planned End Date changed from 13 Feb 2019 to 29 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top